Ingelheim Boehringer New’s Centre released a press statement announcing that it has expanded its biopharmaceutical development and manufacturing capabilities at its cell culture and microbial sites in Biberach, Germany and in Vienna, Austria
The press statement said that 17 million Euros has been invested which has meant the expansion of Boehringer Ingelheim’s current GMP (good manufacturing practice) cell banking, process science, cell line development and quality laboratories, all equipped with the latest technologies. These expansions will enhance state-of-the art cell line development with the proprietary BI-HEX® high expression system and microbial strain as well as process development services for the contract manufacturing business.
The expansion has been taylor-suited to fully meet our customer demands in cell culture and microbial process science, especially for our rapidly expanding pre-clinical project portfolio with biotech companies”, commented Dr. Dorothee Ambrosius, Senior Vice President Biopharmaceuticals Global Process Science at Boehringer Ingelheim.
Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates